Potentially Inappropriate Medications

Potentially Inappropriate Medications (PIMs) are drugs where the risk of adverse events outweighs the clinical benefit for specific populations, particularly adults aged 65 and older. This is due to physiological changes associated with aging that affect drug metabolism. The concept is defined by authoritative clinical guidelines, most notably the American Geriatrics Society (AGS) Beers Criteria® and the European STOPP/START criteria. While not ISO/IEC standards, these criteria are considered the gold standard for clinical risk management in geriatric care. In an enterprise risk framework (healthcare organization), managing PIMs is a key component of patient safety and quality assurance programs. It focuses on systematically identifying and mitigating risks in prescribing decisions for vulnerable groups, distinguishing it from general medication errors which can occur in any population.

In enterprise risk management, healthcare organizations apply PIMs criteria to systematically reduce preventable drug-related harm. Implementation involves three key steps: 1) Adopt a standardized PIMs list, such as the Beers Criteria, and integrate it into the Electronic Health Record (EHR) system. 2) Implement a Clinical Decision Support System (CDSS) that triggers real-time alerts to prescribers when a PIM is ordered. 3) Establish interdisciplinary medication reviews, where pharmacists assess the regimens of high-risk patients (e.g., those with polypharmacy) to identify and resolve PIMs with the medical team. Measurable outcomes include a 15-30% reduction in adverse drug events, lower hospital readmission rates, and improved overall patient safety metrics.

Taiwan enterprises (hospitals) face three main challenges in implementing PIMs management. First, fragmented health information across different providers makes it difficult to obtain a complete medication history. Second, clinical inertia and patient preference can create resistance to changing long-standing prescriptions. Third, limitations in the National Health Insurance (NHI) reimbursement policies may restrict access to safer, newer alternative drugs. To overcome these, organizations should maximize the use of Taiwan's national NHI MediCloud system for medication reconciliation. Mitigation strategies include integrating PIMs alerts into EHRs as a quality KPI and advocating for updated reimbursement policies. The priority action is to mandate EHR-integrated PIMs checks before finalizing prescriptions.

Winners Consulting specializes in Potentially Inappropriate Medications for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact